AbbVie: 3 Positives From The Earnings Report
It is no surprise investors have responded positively to AbbVie's latest results considering revenue growth, earnings outlook upgrade, and dividend increase. The company also has growth catalysts in place, especially with its treatment for Parkinson's disease showing positive trial results. However, its P/E is high for now, and its recent acquisition of Aliada Therapeutics risks being a drag on earnings.
AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Robert A. Michael - C hief Executive Officer Jeffrey R.
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View
ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.
Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth
On Wednesday, AbbVie Inc. ABBV reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92.
AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago.
AbbVie Stock Rises After Earnings Beat, Dividend Hike
The drug maker increased dividend by 5.8% to $1.64 per share.
AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq
AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings.
3 Dividend Growth Stocks to Buy and Never Sell
These 3 dividend growth stocks have crushed the market and show no signs of slowing down.
AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
AbbVie Inc ABBV will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours.
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln
U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.
